Andrew M. Rauth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew M. Rauth has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey T. Henderson
Graduate Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, Canada
3 shared publications - Xiao Yu Wu
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
3 shared publications - Azhar Z. Abbasi
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications - Chunsheng He
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications - Elliya Park
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications - Lily Yi Li
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications
Latest Publications
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- Open Access
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Brain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Open AccessBrain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem)
Abstract LB-096: Blood-brain barrier-penetrating terpolymer nanoparticles deliver docetaxel and trastuzumab to brain metastases of breast cancer
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem)
Abstract LB-096: Blood-brain barrier-penetrating terpolymer nanoparticles deliver docetaxel and trastuzumab to brain metastases of breast cancer
- 1 January 1991
- Published by Elsevier
- p. 457
ENHANCED HYPOXIC CELL RADIOSENSITIZATION AND CYTOTOXICITY BY DNA TARGETED 2-NITROIMIDAZOLES: MECHANISTIC STUDIES
- 1 January 1991
- Published by Elsevier
- p. 457
ENHANCED HYPOXIC CELL RADIOSENSITIZATION AND CYTOTOXICITY BY DNA TARGETED 2-NITROIMIDAZOLES: MECHANISTIC STUDIES